HK Stock Market Move | H&H INTL HLDG (01112) rose over 6%, with the three core businesses achieving synergistic growth in the first half of the year, and shareholder returns significantly enhanced.
H&H INTL HLDG (01112) rose over 6%. As of press time, it was up 6%, at HK$18.9, with a turnover of HK$22.2522 million.
H&H INTL HLDG (01112) rose over 6%, up 6% as of press time, at HK$18.9, with a turnover of HK$22.2522 million.
On the news front, in the first half of this year, H&H INTL HLDG achieved revenue of approximately RMB 8.696 billion, a year-on-year increase of 23.9%; net profit of approximately RMB 611 million, a year-on-year increase of about 7.6 times. By business segment, all three major businesses grew. In the first half, the ANC, BNC, and PNC businesses achieved revenue of RMB 3.97 billion, RMB 3.63 billion, and RMB 1.09 billion, respectively, up 13.9%, 45.2%, and 4.8% year-on-year. In terms of dividends, the board declared an interim dividend of HK$0.82 per share, accounting for approximately 50% of adjusted comparable net profit, a significant increase from HK$0.19 per share in the same period last year, with shareholder returns significantly enhanced.
EB SECURITIES believes that looking ahead to the second half, the company will continue to drive sustainable growth in high-margin, high-growth nutritional supplements and infant formula milk powder, increase marketing investment in strategic new product launches and core markets and expansion markets, while continuing to advance deleveraging and maintain a robust capital structure. Changjiang stated that it is bullish on the medium- to long-term upward trend of H&H's business as a nutritional product supplier positioned for the whole family.
Related Articles

LEADS BIOLABS-B (09887) Core Product Vilixin Granted Orphan Drug Designation in Japan
.png)
PARKSON GROUP (03368) entered into a lease agreement for the property located at Zijin Plaza, Mianyang City.

Policy bottom + valuation rebound, has the real estate industry reached a turning point?
LEADS BIOLABS-B (09887) Core Product Vilixin Granted Orphan Drug Designation in Japan

PARKSON GROUP (03368) entered into a lease agreement for the property located at Zijin Plaza, Mianyang City.
.png)
Policy bottom + valuation rebound, has the real estate industry reached a turning point?






